GTB-3550 Tri-Specific Killer Engager (TriKE®) for High Risk Hematological Malignancies
Status:
Active, not recruiting
Trial end date:
2025-08-01
Target enrollment:
Participant gender:
Summary
This is a multi-center Phase I/II clinical trial of GTB-3550 (CD16/IL-15/CD33) tri-specific
killer cell engager (TriKE®) for the treatment of CD33-expressing high risk myelodysplastic
syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis. The
hypothesis is that GTB-3550 TriKE® will induce natural killer cell function by targeting
malignant cells as well as CD33+ myeloid derived suppressor cells (MDSC) which contribute to
tumor induced immunosuppression. Because CD16 is the most potent activating receptor on NK
cells, this single agent may induce a targeted anti-CD33+ tumor response.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
GT Biopharma, Inc. Masonic Cancer Center, University of Minnesota